Premature Ejaculation Treatment Market to grow with a CAGR of 8.90%
Increasing
healthcare infrastructure and a supportive regulatory environment are the major
drivers for the Global Premature Ejaculation Treatment Market.
According
to TechSci Research report, “Global Premature Ejaculation Treatment Market Industry
Size, Share, Trends, Competition, Opportunity and Forecast, 2018-2028”, Global Premature Ejaculation
Treatment Market has valued at USD 1.33 billion in 2022 and is anticipated to witness
an impressive growth in the forecast period with a CAGR of 7.40% through 2028. This
can be due to collaborations and partnerships among leading companies with a
diverse approach to merge the expertise of individual companies and to
strengthen their position in the market.
Telemedicine
and online resources play a significant role in driving the demand for
Premature Ejaculation Treatment (PE) Market. Telemedicine platforms enable
individuals to consult with healthcare providers remotely, making it easier for
those with premature ejaculation to access medical advice and treatment
options. This is particularly beneficial for individuals in rural or
underserved areas. Telemedicine offers a level of privacy and convenience that
may encourage individuals to seek help for sensitive issues like premature
ejaculation. Patients can discuss their concerns from the comfort and privacy
of their homes. Online platforms can connect patients with healthcare providers
who specialize in sexual health and PE treatment. This ensures that patients
receive expert advice and treatment tailored to their needs. Online resources
may include self-help tools, such as behavioral therapy programs or apps, that
individuals can use to address premature ejaculation. These tools empower
patients to take an active role in their treatment. Telemedicine also includes
teletherapy and online counseling services, which can be effective in
addressing the psychological aspects of premature ejaculation. Patients can
access therapy from the comfort of their homes. Telemedicine allows for
follow-up consultations and progress monitoring, ensuring that patients receive
ongoing support and adjustments to their treatment plans if necessary. Online
resources and telemedicine have a global reach, making information and expert
advice on premature ejaculation accessible to individuals worldwide. This can
drive demand for treatments in various regions.
Lifelong
(primary) PE is a condition that has affected a male throughout his life,
typically from the beginning of his first sexual experience. On the other hand,
acquired (secondary) PE is a condition in which a male who has previously had a
normal sex life begins to experience PE. While the exact cause of PE is not
fully understood, it can be attributed to a combination of psychological and
biological factors. These factors may include early sexual experiences, a
history of sexual abuse, body image issues, depression, anxiety, abnormal
hormone levels, genetic predisposition, inflammation or infection of the
prostate or urethra, and concerns related to premature ejaculation.
In October 2022, Morari, an innovative company focused
on sexual health and wellness, has unveiled its equity-based community round
campaign through the investment platform Wefunder. This initiative aims to
secure funding for the final stages of product development, gain regulatory
clearance, and prepare for the upcoming launch of its groundbreaking Mor patch.
Remarkably, within just a few days of its commencement, the campaign has
already surpassed 50 percent of its initial funding target. Morari was established
with the primary objective of alleviating the challenges posed by premature
ejaculation, which can cause significant distress for men and their partners.
This condition is the most prevalent male sexual dysfunction, impacting
approximately 30 percent of men. Additionally, there is a substantial 40
percent of men who may not meet the formal criteria for premature ejaculation
but still desire to prolong their endurance during sexual activity.
Browse
over XX market data Figures and spread through 110 Pages and an in-depth TOC
on "Premature Ejaculation Treatment Market.”
The
lack of standardization is indeed a challenge in the Global Premature
Ejaculation Treatment Market. Without standardized treatment guidelines, there
can be variations in the approach to diagnosing and treating premature
ejaculation. This can lead to inconsistencies in the care provided to patients
and affect treatment outcomes. The absence of standardized diagnostic criteria
for premature ejaculation can make it challenging to consistently identify and
categorize individuals with the condition. This can result in underdiagnosis or
misdiagnosis. Lack of standardized treatment protocols means that healthcare
providers may use different methods and medications to address premature
ejaculation. This can result in variations in treatment effectiveness and
patient experiences. The absence of standardized outcome measurement tools can
make it difficult to assess the success or efficacy of different treatment
approaches. It hinders the ability to compare the results of various treatments
in a meaningful way. Standardized patient education materials and resources are
important for helping individuals understand their condition and treatment
options. Lack of standardization can lead to inconsistent and potentially
inaccurate information being provided to patients. The lack of standardized
treatment guidelines and criteria can create challenges for regulatory agencies
in evaluating and approving medications and therapies for premature
ejaculation. This can impact the availability of approved treatments.
Standardization is essential for ensuring the quality and safety of care
provided to individuals with premature ejaculation. Without standardized
practices, there is a risk of suboptimal care and potential safety concerns.
Global Premature Ejaculation Treatment Market is
segmented based on Drug Type, Type, By Dosage Form, Distribution Channel, and
by region.
Based on Drug
Type, Global Premature Ejaculation Treatment Market is segmented into Dapoxetine,
Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake
Inhibitors, Topical Anesthetics, and Zertane. Selective Serotonin Reuptake
Inhibitors (SSRIs) are a class of medications primarily used to treat
depression, anxiety disorders, and certain other mental health conditions.
These drugs are named for their specific mechanism of action, which involves
increasing the levels of serotonin, a neurotransmitter, in the brain. While
SSRIs are commonly used for mood disorders, they can also have applications in
treating other conditions, including Premature Ejaculation (PE). Several SSRIs are available as prescription
medications. Common SSRIs include fluoxetine (Prozac), sertraline (Zoloft),
paroxetine (Paxil), escitalopram (Lexapro), and citalopram (Celexa). SSRIs are primarily prescribed to treat mood
disorders, such as major depressive disorder, generalized anxiety disorder,
social anxiety disorder, obsessive-compulsive disorder, and panic disorder. They
are also used in the treatment of post-traumatic stress disorder (PTSD),
premenstrual dysphoric disorder (PMDD), and other conditions.
Based on Region, North America dominated the Global Premature Ejaculation Treatment Market. The
cultural openness and willingness to discuss sexual health issues in North
America contribute to higher rates of diagnosis and treatment seeking. Reduced stigma
surrounding sexual health concerns encourages individuals to seek help. Pharmaceutical
companies in North America often invest heavily in marketing and advertising
their products, which can lead to increased awareness and demand for premature
ejaculation treatments. North America has well-established regulatory agencies,
such as the FDA in the United States, which set standards for drug approvals
and ensure the safety and efficacy of pharmaceutical treatments. This
regulatory framework can encourage pharmaceutical companies to invest in
research and development for premature ejaculation treatments. While access to
healthcare can vary within the region, in general, North America has relatively
good access to healthcare services, making it easier for individuals to consult
healthcare professionals for premature ejaculation treatment.
The Asia-pacific region witnesses the fastest growth in
the Global Premature Ejaculation
Treatment Market. The Asia-Pacific region is home to a vast and diverse population,
including countries like China and India with exceptionally large populations.
The sheer number of potential patients seeking treatment for premature
ejaculation contributes to market growth. Cultural attitudes toward sexual
health and discussions about sexual dysfunction are evolving in many APAC
countries. Increasingly, people are becoming more open to addressing and
seeking treatment for sexual health issues, including premature ejaculation.
There is a growing awareness of sexual health concerns in the APAC region,
driven by healthcare education, public health campaigns, and access to
information through the internet and media. This heightened awareness
encourages individuals to seek help for premature ejaculation. Rapid
urbanization in many APAC countries has led to lifestyle changes that can
impact sexual health. Stress, anxiety, and other factors associated with urban
living may contribute to premature ejaculation, prompting individuals to seek
treatment.
Some
of the major companies operating in the Global
Premature Ejaculation Treatment Market include:
- Absorption
Pharmaceuticals Inc.
- Allergan
PLC
- AstraZeneca
PLC
- Bayer
AG
- Eli
Lilly and Company
- GlaxoSmithKline
PLC
- Innovus
Pharmaceuticals Inc.
- Merck
& Co., Inc.
- Pfizer,
Inc.
- Teva
Pharmaceutical Industries Ltd.
Download Free Sample Report
Customers can also request 10% free
customization on this report.
“Certain areas, particularly in North
America, are projected to exert significant demand for Premature Ejaculation
Treatment. The growth in the competitive landscape and the presence of
well-established companies in the market, committed to enhance the overall
wellbeing of people each year, are expected to contribute to a remarkable
growth of the Global Premature Ejaculation Treatment Market in the forecast
period," said Mr. Karan Chechi, Research Director with TechSci Research, a
research-based Global management consulting firm.
Premature Ejaculation Treatment Market – Global Industry Size, Share,
Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type (Dapoxetine,
Phosphodiesterase Type 5 (PDE5) Inhibitors, Selective Serotonin Reuptake
Inhibitors, Topical Anesthetics, and Zertane), By Type (Oral Therapies and Topical Therapies), By Dosage Form (Pills and
Spray), By Distribution Channel (Hospitals, Online Pharmacies, and Retail
Pharmacies), by region, and Competition evaluated
the future growth potential of Global Premature Ejaculation Treatment Market and
provides statistics & information on market size, structure, and future
market growth. The report intends to provide innovative market intelligence and
help decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Premature Ejaculation Treatment Market.
Contact
Mr.
Ken Mathews
Techsci
Research LLC
420
Lexington Avenue, Suite 300,
New
York, United States- 10170
Tel:
+13322586602
Email: [email protected]
Website: www.techsciresearch.com